Merck KGaA (FRA:MRK) has earned an average rating of “Hold” from the twenty-two ratings firms that are currently covering the firm, MarketBeat Ratings reports. Twelve investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is €108.11 ($128.70).
MRK has been the topic of several analyst reports. Kepler Capital Markets set a €119.00 ($141.67) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Thursday, September 21st. Morgan Stanley set a €103.00 ($122.62) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Monday, September 25th. Citigroup set a €123.00 ($146.43) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Monday, September 25th. UBS Group initiated coverage on shares of Merck KGaA in a research report on Tuesday, September 26th. They set a “buy” rating and a €120.00 ($142.86) price target on the stock. Finally, Warburg Research set a €115.00 ($136.90) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Tuesday, September 26th.
Shares of Merck KGaA (MRK) opened at €90.22 ($107.40) on Friday. Merck KGaA has a 52-week low of €87.33 ($103.96) and a 52-week high of €115.00 ($136.90). The company has a market cap of $11,680.00 and a PE ratio of 21.13.
COPYRIGHT VIOLATION WARNING: This news story was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3145488/merck-kgaa-mrk-receives-consensus-rating-of-hold-from-analysts.html.
About Merck KGaA
MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.